Did Martin Shkreli Just Send KaloBios Pharmaceuticals Inc (KBIO) Stock Soaring with $100 Million Investment Plan?


Can one man’s words send a stock soaring over 50%? This may be the case after Pharmaceutical “villain” Martin Shkreli went onto Bloomberg TV to discuss his investment and turnaround plan for KaloBios Pharmaceuticals Inc (NASDAQ:KBIO). That plan evidently includes a $100 million investment on Shkreli’s behalf.

For those who don’t recall, Shkreli infuriated millions when he decided to increase the price of popular HIV drug Daraprim frmo $13.50 to $750 per pill back in August. Evidently he feels as though KBIO has a shot at becoming a profitable pharmaceutical company, even after its NASDAQ delisting notice earlier this month.

The stock price has soared today, more than likely because of Shkreli’s words on the company, and his pending “plan. The stock is up 50.21% or $9.24 after the positive news, hitting $27.64 per share. About 7.70 million shares traded hands or 243.75% up from the average. KBIO has risen 3185.71% since April 23, 2015 and is uptrending. It has outperformed by 3186.84% the S&P500.

The institutional sentiment increased to 0.45 in Q2 2015. Its up 0.04, from 0.41 in 2015Q1. The ratio increased, as 8 funds sold all KaloBios Pharmaceuticals Inc shares owned while 3 reduced positions. 2 funds bought stakes while 3 increased positions. They now own 6.90 million shares or 22.14% less from 8.87 million shares in 2015Q1.

Opus Point Partners Management Llc holds 0.28% of its portfolio in KaloBios Pharmaceuticals Inc for 746,467 shares. Harbourvest Partners Llc owns 57,604 shares or 0.01% of their US portfolio. Moreover, Blair William & Co Il has 0% invested in the company for 53,635 shares. The California-based California Public Employees Retirement System has invested 0% in the stock. Citigroup Inc, a New York-based fund reported 2,745 shares.

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $74.50 million. The Firm is focused on the development of monoclonal antibody therapeutics for diseases that represent a burden to society and to patients and their families. It currently has negative earnings. The Firm operates through the development of pharmaceutical products segment.